ASUS VivoWatch ECG App Achieves FDA Certification in Thailand

On July 1, 2025, ASUS announced the certification of its VivoWatch ECG app by the Food and Drug Administration of Thailand (FDA Thai), marking a significant milestone in the realm of smart healthcare technology. This certification underscores ASUS's commitment to delivering innovative, medical-grade health monitoring solutions that cater to both individual users and healthcare institutions globally.

The VivoWatch ECG app allows users to measure their electrocardiogram (ECG) readings directly on the ASUS VivoWatch device. According to Joe Hsieh, Chief Operating Officer and Global Senior Vice President at ASUS, "Our goal is to empower individuals and healthcare providers with the best health monitoring tools. This certification validates our technology and reinforces our commitment to expanding global access to smart, medical-grade health solutions."

The app's functionality is straightforward: users simply place a fingertip on the watch's sensors for thirty seconds to obtain their ECG readings, which can then be shared with healthcare providers. This feature is compatible with the latest models of the ASUS VivoWatch, including the VivoWatch 6 and VivoWatch 6 AERO.

The introduction of the ECG monitoring capability not only serves individual consumers but also positions the VivoWatch as a valuable tool in hospitals and clinics, where it can contribute to enhanced patient care and operational efficiency. According to a report by the World Health Organization published in April 2023, mobile health technologies like the VivoWatch have been shown to improve health outcomes by facilitating timely medical interventions.

In addition to ECG monitoring, the VivoWatch also includes features for blood pressure monitoring, enabling users to track two vital cardiovascular indicators simultaneously. This dual functionality is particularly appealing to healthcare providers seeking to improve patient monitoring and care management.

Experts in digital health, such as Dr. Emily Chen, a professor at the University of California, Berkeley, emphasize the growing importance of personal health technologies in preventative healthcare. "The integration of ECG monitoring into wearable devices represents a significant leap toward empowering patients to take charge of their health, especially in regions with limited access to traditional healthcare facilities," Dr. Chen noted in her 2024 study published in the Journal of Medical Internet Research.

As smart health technologies gain traction, ASUS's certification is timely, aligning with increasing global demand for remote health monitoring solutions. The COVID-19 pandemic has accelerated the adoption of telehealth services, with a report from the Centers for Disease Control and Prevention indicating a 154% increase in telehealth visits between 2019 and 2021.

Looking ahead, the implications of this certification extend beyond individual health management. The ASUS VivoWatch could play a crucial role in institutional settings, enhancing the quality of care provided in hospitals and clinics. Dr. Robert Hill, a healthcare technology analyst at Gartner, predicts that "the integration of wearables in clinical settings will not only improve patient management but also streamline operations, leading to cost savings and better health outcomes over time."

In conclusion, the FDA certification of the ASUS VivoWatch ECG app marks a pivotal moment in the intersection of technology and healthcare, heralding a new era of personal health management tools that promise to empower users while simultaneously enhancing institutional healthcare delivery. As the global health landscape continues to evolve, ASUS's commitment to innovation positions it as a leader in the digital health arena, with potential implications for future healthcare practices worldwide.